Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PolyRemedy, Inc.
The advanced wound care market is attracting an increasing number of competitors and investors seeking a stake in this high-need, high-growth space. But although the number of innovative wound care products is on the rise, this is also a highly diverse market, with some striking differences among various regions of the world in terms of product adoption and standard wound care practices.
Large numbers of patients with chronic wounds haven’t responded to existing treatments, and their open wounds can have dire consequences. The suffering of patients, the failures of past remedy attempts, and new financial pressures on hospitals have medtech entrepreneurs and venture investors focused on finding better solutions to wound care.
During the second quarter of 2011, 57 medical device companies brought in a total of $1.7 billion in financings. The M&A activity reached $28.8 billion, unusually high due to Johnson & Johnson's $21.7 billion takeover of orthopedic device maker Synthes. VC funding represented $76 million or 43% of the second quarter's in vitro diagnostics/research financing aggregate of $177 million. A hefty $4.1 billion was spent on 11 in vitro diagnostic/research M&A transactions, the largest being Thermo Fisher's $3.5 billion buy of Swedish genetics testing firm Phadia AB.
- Digital Health
- Infection Control-Sterilization
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.